Trial · NCT05796388
A Study of Virtual Reality and Linaclotide for IBS-C
The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treat
- Status
- Recruiting
- Sponsor
- Mayo Clinic
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 65 participants (planned)
- Start
- May 31, 2024
- Primary completion
- October 2026
- Conditions
- Irritable Bowel Syndrome With Constipation
Summary
The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.
Interventions
- Virtual Reality Device
Locations
1 country: United States.
| Facility | City | Country |
|---|---|---|
| Mayo Clinic Florida | Jacksonville, Florida | United States |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.